Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: EBS stock price vs CRH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CRH's multiple
Needs CRH P/E.
Implied fair value · at EBS's multiple
Needs EBS P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EBS FY 2025 (ended Dec 31, 2025) · CRH FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
EMERGENT BIOSOLUTIONS INC. · implied price per share
Bear
$33.45
Base
$39.35
Bull
$45.26
CRH public limited company · implied price per share
Bear
$61.82
Base
$72.72
Bull
$83.63
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.92x
0.75x
Net debt / EBITDA
Leverage against operating earnings
2.45x
1.75x
Cash and equivalents
Liquid reserves on the balance sheet
$205.40M
$4.10B
Total debt
Interest-bearing obligations outstanding
$1.00B
$18.71B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
EBS vs MRNA
SIGA TECHNOLOGIES INC
EBS vs SIGA
Amphastar Pharmaceuticals, Inc.
EBS vs AMPH
CATALYST PHARMACEUTICALS, INC.
EBS vs CPRX
Organon & Co.
EBS vs OGN
PERRIGO Co plc
EBS vs PRGO
MARTIN MARIETTA MATERIALS INC
EBS vs MLM
Vulcan Materials CO
EBS vs VMC
CEMEX SAB DE CV
EBS vs CX
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe EBS can stabilize revenue decline and sustain its stronger margin profile without worsening leverage, then the stock could offer rerating upside because it trades at a clear discount to CRH on P/E and P/S while sitting near the low end of its historical range.
EBS trades at a clear valuation discount versus CRH on every major multiple shown, with the biggest gap on P/E and P/S. The market appears to be pricing in EBS's negative revenue growth and weaker quality metrics despite its lower absolute multiples.
Supporting Metrics
